Torii Pharmaceutical Co., Ltd (Torii) (TSE: 4551) has announced that TOA EIYO LTD. (TOA EIYO) will acquire the marketing authorization and take over the marketing activities for uricosuric agent URINORM Tablet 50mg and 25mg from Torii on April 1, 2020.

Rationale of the transfer

URINORM has long been used for treatments of gout and hyperuricemia for many patients as one of main products of Torii since 1979. Torii intends to focus on extending and maximizing values of the new products and transfer URINORM, based on the drastic reform of the drug price system.

Overview of the transfer

Products

URINORM Tablet 50mg

URINORM Tablet 25mg

Indication

Gout Hypertension accompanied by hyperuricemia

Launch

URINORM Tablet 50mg April, 1979

URINORM Tablet 25mg June, 1984

Sales 600 milliion yen in 2018

TOA EIYO will be responsible for not only providing and gathering URINORM's information but also supplying URINORM stably from April 1, 2020. Torii will continue to be responsible for distribution.

Torii will receive a consideration from TOA EIYO. TOA EIYO and Torii don't disclose the amount of consideration because of business circumstances.

Overview of TOA EIYO

Name TOA EIYO LTD.

Address 10-6,Hatchobori 3-chome,Chuo-ku,Tokyo,Japan

Representative President : Atsuo Takahashi

Business Manufacture and Sale of Pharmaceuticals

Capital 300million yen

Foundation October,1943

Total Equity 54,555 million yenAs of March 31,2019

Total Assets 65,015 million yenAs of March 31,2019

Schedule

The date of Decision November 25, 2019

The date of agreements November 25, 2019

The date of transfer April 1, 2020

Impact on Financial Performance

The effects of this transfer on the business performance of Torii's in this fiscal year will be immaterial.The effects on the business performance for the fiscal year ending December 2020, are to be included in Torii's forecasts to be announced on February 6, 2020.

Contact:

Tel: +81-3-3231-6814

(C) 2019 Electronic News Publishing, source ENP Newswire